| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10930860 | Cytotherapy | 2012 | 8 Pages |
Abstract
A low dose of Dex favors MSC expansion in vitro, and protects against apoptosis. It is not suitable for MSC to be pre-treated with Dex when they are to be used to treat immunologic disease. However, when MSC are applied to promote angiogenesis, it is beneficial for them to be pre-treated with 10â9Â mol/L Dex.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Hanyu Wang, Bo Pang, Yan Li, Delin Zhu, Tianxiang Pang, Yongjun Liu,